Chas Mckhann Purchases 37,500 Shares of XGN
Chas Mckhann increased his stake in XGN with a purchase of 37,500 shares.
Key Points
- Chas Mckhann bought 37,500 shares of XGN on June 9, 2026, at an undisclosed price.
- Shares of XGN traded at $4.45 on Monday, with several peers adjusting their holdings recently.
- Analysts from BTIG and Canaccord Genuity maintained 'buy' ratings with price targets up to $10.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chas Mckhann made a notable move by purchasing 37,500 shares of XGN on June 9, 2026. This transaction adds to a series of insider buys, reflecting continued interest in the company from those closely tied to it.
Other Institutional Activity in XGN
In recent moves among institutional investors, Wexford Capital LP increased its holdings by 326,077 shares, reaching a total of 792,855 shares valued at approximately $2.38 million. Acadian Asset Management LLC also boosted its position by 274,666 shares, ending with 689,114 shares worth about $2.06 million. Vanguard Capital Management LLC opened a new position with 678,652 shares valued at $2.04 million. Meanwhile, Balysany Asset Management L.P. reduced its stake by 122,555 shares, holding 796,632 shares valued at $2.39 million.
Exagen Inc. Stock Down 39.8%
Shares of XGN traded near $4.45 on Monday. The stock has seen various institutional movements, with some increasing and others decreasing their stakes. This activity comes as the stock navigates its 52-week range and market dynamics.
$XGN stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Exagen Inc.
Several insiders have been active in buying XGN shares. On June 9, 2026, Frank Stokes, Scott Kahn, and Chas Mckhann each purchased 37,500 shares. Earlier in March, John Aballi, President and CEO, acquired 100,000 shares at $3.16 and an additional 150,000 shares at no disclosed price. Jeffrey Black, the Chief Financial Officer, also bought 75,000 shares at $3.16 on the same day.
Analysts Set New Price Targets
BTIG maintained a 'buy' rating on XGN, setting a price target of $8 on May 12, 2026. Canaccord Genuity also maintained its 'buy' rating, with a target of $8 on April 20, 2026. Other firms like Craig-Hallum and Keybanc have also kept 'buy' ratings with targets reaching $10.
Bottom Line
Chas Mckhann's recent purchase of XGN shares is part of a broader pattern of insider buying, suggesting confidence in the company's prospects. Institutional investors have shown mixed activity, with some increasing and others trimming their stakes. Analysts remain bullish, maintaining 'buy' ratings with optimistic price targets. As always, it's important to consider these insights as part of a broader investment strategy.
Get Exagen Inc. alerts
New 13F filings, insider trades, and analyst moves on $XGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.